A universal vaccine against B meningococcus;Vacuna universal frente a meningococo B

Anales de Pediatria Continuada

Volumn 9, Issue 1, 2011, Pages 60-63

  Rodríguez Tenreiro, Carmen ^a   Martinón Torres, Federico ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; MENINGOCOCCOSIS;

EID: 79952409051     PISSN: 16962818     EISSN: 16964608     Source Type: Journal    
DOI: 10.1016/S1696-2818(11)70008-7     Document Type: Article

References (25)

1. Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis. 2009;9:418-27.
2. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005;5:21-30. (Pubitemid 40037626)
3. Finne J, Leinonen M, Mäkelä P. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355-7. (Pubitemid 13028927)
4. Wyle F, Artenstein M, Brandt B, Tramont E, Kasper D, Alteiri P. Immunologic response of man to group B polysaccharide vaccines. J Infect Dis. 1972;126:514-22.
5. Mandrell R, Zollinger W. Measurement of antibodies to meningococcal group B polysaccharide:Low avidity binding and equilibrium binding constants. J Immunol. 1982;129:2172-8. (Pubitemid 12004390)
6. Jennnings H, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986;137:708-10.
7. Devoe IW, Gilchrist JE. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med. 1973;138:1156-67.
8. Peeters C, Rümke H, Sundermann L, Rouppe van der Voort E, Meulenbelt J, Schuller M, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine. 1996;14:1009-15. (Pubitemid 26271075)
9. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet. 2002;359:1499-508. (Pubitemid 34457772)
10. Sexton K, Lennon D, Oster P, Aaberge I, Martin D, Reid S, et al. Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March. 2004, Auckland, New Zealand. N Z Med J. 2004;117:1 p preceding U1027.
11. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23:2191-96. (Pubitemid 40341449)
12. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specifi c MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007;25:3075-79. (Pubitemid 46482737)
13. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23:2191-96. (Pubitemid 40341449)
14. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009;38:413-8.
15. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines -an unfinished story. Lancet Infect Dis. 2010;10:112-24.
16. Borrow R, Goldblatt D, Balmer P, Dawson M, Andrews N, Miller E, et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine. 2002;20:2592-96. (Pubitemid 34615600)
17. Zollinger WD, Donets M, Brandt BL, Ionin B, Moran EE, Schmiel D, et al. Multivalent group B meningococcal vaccine based on Native Outer Membrane Vesicles (NOMV) has potential for providing safe, broadly protective immunity. 16th International Pathogenic Neisseria Conference. 2008; Rotterdam, Netherlands; Sept 7-12. 2008. Abstract O35.
18. Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE, et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 2010. En prensa.
19. Nissen MD, Marshall HS, Richmond P, Lambert SB, Roberton D, Gruber WC, et al. A randomized, placebo controlled, double-blind, phase 1 trial of ascending doses of meningococcal group rLP2086 vaccine. En: Proceedings of the 26th annual meeting of the European Society for Paedriatric Infectious Diseases. 2008.
20. Giuliani MM, Santini L, Brunelli B, Biolchi A, Arico B, Di Marcello F, et al. The region comprising amino acids 100-255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun. 2005;73:1151-60. (Pubitemid 40165775)
21. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692-00.
22. Litt DJ, Savino S, Beddek A, Comanducci M, Sandiford C, Stevens J, et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis. 2004;190:1488-97. (Pubitemid 39332190)
23. Giuliania MM, Biolchia A, Serrato D, Ferlicca F, Vienken K, Oster P, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28:5023-30.
24. Vesikari T. Immunogenicity of an Investigational Multicomponent Meningococcal Serogroup B Vaccine in Healthy Infants at 2, 4 and 6 Months of Age, presented at the 17th International Pathogenic Neisseria Conference, September 11-16, 2010, Banff, Canada.
25. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, et al. International Meningococcal Genetics Consortium. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet. 2010;42:772-6.